Kisspeptin signalling.
Upstream neuronal control of GnRH release and reproductive-hormone pulsatility.
Kisspeptin sits above gonadotropin-releasing hormone in the reproductive hierarchy and is the reason the axis has a pulse at all. It signals through KISS1R, a Gq/11-coupled G-protein-coupled receptor formerly called GPR54, expressed densely on GnRH neurons in the hypothalamus. Receptor binding activates phospholipase C signalling, which depolarises those neurons and drives GnRH release into the hypophyseal portal circulation, and from there the pituitary secretes luteinizing hormone and, more modestly, follicle-stimulating hormone. The pathway's importance was established through human genetics rather than pharmacology. Loss-of-function mutations in KISS1R cause failure to enter puberty with low gonadotropins, and activating mutations are associated with precocious puberty. That is unusually clean evidence: it shows the receptor is not merely involved but required, which is a stronger claim than most peptide pathways can make. A specific population of kisspeptin neurons in the arcuate nucleus co-expresses neurokinin B and dynorphin, and these cells are widely regarded as the pulse generator for the whole axis. Neurokinin B provides the excitatory drive that starts each pulse and dynorphin provides the inhibition that ends it, producing the rhythmic output that GnRH neurons then translate into pulsatile secretion. Kisspeptin neurons are also where metabolic and steroid feedback signals converge, which is a plausible mechanistic bridge between energy availability and reproductive function. Administering kisspeptin therefore stimulates the axis in a way that is physiologically upstream, working through the body's own GnRH neurons rather than substituting for GnRH. In principle this preserves more of the natural regulatory structure. As with GnRH itself, the pattern matters: sustained exposure can desensitise the system rather than sustain it. On clinical relevance, this is a research tool rather than a treatment. Kisspeptin has been used in human studies as a probe of reproductive axis function and has been explored for triggering oocyte maturation in fertility settings, and its acute effect on LH in people is reproducible. It is not an approved medicine, there are no established therapeutic protocols, and its short circulating half-life makes practical use awkward. Claims about libido or hormonal enhancement outside supervised research go well beyond what the pathway evidence supports. It is also worth separating two distinct ideas that are often merged: kisspeptin's role as a necessary component of normal reproductive physiology is firmly established, while the proposition that supplying additional kisspeptin improves anything in a person with an intact axis is a separate claim that has not been demonstrated.
Peptides acting through this pathway.
FAQ.
What does kisspeptin signalling do?
Kisspeptin sits above gonadotropin-releasing hormone in the reproductive hierarchy and is the reason the axis has a pulse at all. It signals through KISS1R, a Gq/11-coupled G-protein-coupled receptor formerly called GPR54, expressed densely on GnRH neurons in the hypothalamus. Receptor binding activates phospholipase C signalling, which depolarises those neurons and drives GnRH release into the hypophyseal portal circulation, and from there the pituitary secretes luteinizing hormone and, more modestly, follicle-stimulating hormone. The pathway's importance was established through human genetics rather than pharmacology. Loss-of-function mutations in KISS1R cause failure to enter puberty with low gonadotropins, and activating mutations are associated with precocious puberty. That is unusually clean evidence: it shows the receptor is not merely involved but required, which is a stronger claim than most peptide pathways can make. A specific population of kisspeptin neurons in the arcuate nucleus co-expresses neurokinin B and dynorphin, and these cells are widely regarded as the pulse generator for the whole axis. Neurokinin B provides the excitatory drive that starts each pulse and dynorphin provides the inhibition that ends it, producing the rhythmic output that GnRH neurons then translate into pulsatile secretion. Kisspeptin neurons are also where metabolic and steroid feedback signals converge, which is a plausible mechanistic bridge between energy availability and reproductive function. Administering kisspeptin therefore stimulates the axis in a way that is physiologically upstream, working through the body's own GnRH neurons rather than substituting for GnRH. In principle this preserves more of the natural regulatory structure. As with GnRH itself, the pattern matters: sustained exposure can desensitise the system rather than sustain it. On clinical relevance, this is a research tool rather than a treatment. Kisspeptin has been used in human studies as a probe of reproductive axis function and has been explored for triggering oocyte maturation in fertility settings, and its acute effect on LH in people is reproducible. It is not an approved medicine, there are no established therapeutic protocols, and its short circulating half-life makes practical use awkward. Claims about libido or hormonal enhancement outside supervised research go well beyond what the pathway evidence supports. It is also worth separating two distinct ideas that are often merged: kisspeptin's role as a necessary component of normal reproductive physiology is firmly established, while the proposition that supplying additional kisspeptin improves anything in a person with an intact axis is a separate claim that has not been demonstrated.
Which peptides act through kisspeptin signalling?
Kisspeptin. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.